Company: CMND
Filing Date: 2025-06-12
Form Type: POS AM
Source: 0001213900-25-053898
Chunk: 1

Company: Clearmind Medicine Inc.
Filing Date: 2025-06-12
Form: POS AM
Chunk 1
---
 and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. ☐

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ☒

If an emerging
growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards † provided pursuant
to Section 7(a)(2)(B) of the Securities Act. ☐

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

<div align='center'>EXPLANATORY NOTE</div>

Clearmind Medicine Inc., or the Registrant, filed
with the Securities and Exchange Commission, or the SEC, a Registration Statement on Form F-1 (Registration No. 333-276913) on February
7, 2024, which was declared effective by the SEC on February 16, 2024, or the Registration Statement. The Registration Statement originally
covered the resale from time to time by the Selling Shareholder identified in the prospectus that form a part of the Registration Statement
of up to 1,500,000 common shares, no par value, or the Common Shares, issuable upon the exercise of warrants originally issued in a private
placement on January 16, 2024.

On
March 20, 2024, the Registrant filed Post-Effective Amendment No. 1 to update and supplement information contained in the Registration
Statement, and also to include updated financial information. Post-Effective